跳至主要内容
临床试验/NCT04171427
NCT04171427Unknown不适用

Evaluation of the Efficacy and the Cutaneous Acceptability of a Dermocosmetic Product in the Repigmentation of Vitiligo -Study Realized by a Dermatologist-

Laboratoire Dermatologique ACM1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2019年11月21日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
12
试验地点
1
主要终点
the percentage of repigmentation

研究概览

简要总结

  • Study in proof of concept;
  • Double blind study;
  • Comparative study, versus placebo in intra-individual
  • Three parallel groups testing different dosages / combinations of treatments
  • Randomized.

详细描述

This study has as objectives:

Primary objective :

• Evaluate the percentage of repigmentation observed one month after the end of three months of treatment measured on an objective layer by image analysis;

Secondary objectives:

Evaluate:

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Inclusion Criteria: Sexe: female and male;
  • Age: over 18 years old;
  • Patients with stable non-segmental vitiligo lesions (defined as no new lesions or lesions that have been present for at least 3 months, lack of hypochromic margins in Wood's lumen and absence of confetti depigmentation);
  • Patients with 2 to 6 symmetrical lesions (1 to 3 on each side). These lesions (macules) will be treated for a minimum surface of 2 cm² and a maximum surface of 100 cm².
  • Healthy volunteer;
  • Volunteer having given in writing his free, informed and express consent;
  • Volunteer willing to abide by the protocol and procedures of the study.

排除标准

  • Pregnant woman or woman who is breastfeeding or planning for early pregnancy during the study;
  • Patient with segmental or mixed vitiligo;
  • Patient with vitiligo of the external genitalia;
  • Patient with vitiligo touching hands and feet only
  • Patient with a history of skin cancer or pre-cancerous skin lesions;
  • Patient taking topical or systemic vitiligo treatments in the month prior to the start of the study;
  • Patient taking concomitant local or general corticosteroid therapy or immunomodulatory therapy;
  • Patient with a history of photodermatoses or taking photosensitizing medications;
  • Patient having planned to expose himself (artificial sun or UV) during the study at the level of the zones to be treated and / or having been exposed during the month preceding the beginning of the study and having an acquired pigmentation (tanning) obvious;
  • Patient who had been treated with phototherapy within 4 weeks before randomization;
  • Patient with lithium allergy.

结局指标

主要结局

the percentage of repigmentation

时间窗: 4 months

• Evaluate the percentage of repigmentation observed one month after the end of three months of treatment measured on an objective layer by image analysis;

次要结局

  • the percentage of repigmentation and acceptability(1 month, 2 months, 3 months)

研究者

发起方
Laboratoire Dermatologique ACM
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验